جستجوی استاد راهنمای دانشگاهی

Ann L. Obergمشاهده پروفایل

استاد

• Ovarian Cancer
• Pancreatic Cancer
• Large-scale Genomic Data Analysis
• +۵ مورد دیگر

Ann L. Oberg is a Professor of Biostatistics at Mayo Clinic College of Medicine and Science, holding full faculty privileges. She serves as Director of the Biostatistics Core for the Mayo Clinic Ovarian and Pancreatic Cancer SPORE programs, and Director of the Computational Genomics and Bioinformatics Unit for the Alliance for Clinical Trials in Oncology. Her work focuses on genomic data analysis, cancer risk modeling, and clinical trial design. Education: PhD in Statistics, North Carolina State University MS in Biometry, University of Nebraska-Lincoln BS in Mathematics, University of Nebraska at Kearney Research Interests: Dr. Oberg specializes in large-scale genomic data analysis (mRNA, protein mass spectrometry, DNA methylation) to identify disease markers and improve treatment strategies for ovarian and pancreatic cancers. She develops prognostic models, experimental designs for xenograft studies, and normalization methods for genomic datasets. Grants & Projects: Multifactor Risk Score Development (NIH, 2023-2025) Pancreatic Cancer Detection Coordination (NIH, 2022-2025) Uterine Serous Carcinoma Therapeutics (NIH, 2009-2025) Labs/Teams: Leads the Computational Genomics and Bioinformatics Unit and collaborates with the Mayo Clinic Comprehensive Cancer Center, Alliance for Clinical Trials in Oncology, and Pancreatic Cancer Early Detection Program.

• Plant Biotechnology
• Molecular Biology
• Biochemistry
• +۴ مورد دیگر

Dr. Alexandra Machado Ferreira Castilho is a leading researcher at the Institute of Plant Biotechnology and Cell Biology within the University of Natural Resources and Life Sciences, Vienna (BOKU) . She has served as Principal Investigator since 2018 and previously as Scientific Coordinator of the Laura Bassi Center PlantBioP (2010-2017). Her work focuses on Plant Molecular Farming and Glycoengineering , aiming to optimize plant-based production of therapeutically relevant glycoproteins. Specializes in tailoring N-glycan profiles for biopharmaceuticals Develops plant cell factories for antibody and decoy receptor production Key projects include SARS-CoV-2 neutralization strategies and cancer immunotherapy agents Her recent publications analyze glycoengineering techniques in Nicotiana benthamiana , covering topics like ACE2-Fc decoys for viral neutralization, PD1/PDL1 blockade for oncology, and protease suppression for protein stability. She has received funding from the Austrian Science Fund (FWF) for projects on immune checkpoint inhibitors and glycosylation pathway modulation.

• Biocatalysis
• Fungal Enzymes
• Bacterial and Algal Polymers
• +۲ مورد دیگر

Anna Jarosz-Wilkołazka , Professor of Biological Sciences at the Maria Curie-Skłodowska University (UMCS) in Lublin, is affiliated with the Faculty of Biology and Biotechnology and leads research at the Department of Biochemistry and Biotechnology . With expertise spanning fungal enzymes, microbial polymers, and biomaterial modification, her work bridges biochemistry, biotechnology, and environmental science. Current research focuses on biocatalysis in aqueous/non-aqueous systems , fungal enzyme applications (particularly laccases), and the characterization of extracellular polymeric substances (EPS) from bacteria and algae for biosorption and bioflocculation. She has coordinated major research projects including "Modification of biopolymer materials with protease inhibitors" (NCN OPUS 13, 2017-2022) and "Oxalate oxidase in Abortiporus biennis" (NCN Opus 5, 2015-2019). Her recent publications (2016-2023) highlight advancements in fungal laccase immobilization for pollutant removal, EPS applications for heavy metal biosorption, and novel bioactive dyes. A 2023 study investigated oxalate oxidase sources in wood-rotting fungi, while 2020 work explored EPS from endophytic Fusarium culmorum strains affecting cereal crops. Earlier studies focused on lignin degradation mechanisms (2017) and EPS-driven biomineralization (2016). As a scientific supervisor, she has guided NCN projects on Rhodococcus opacus EPS properties (2016-2021) and fungal enzyme immobilization techniques (2015-2018). She actively participates in science outreach through initiatives like the Mobile Science Festival and Design Thinking Week under Erasmus+.

• Molecular Oncology
• Tumor Biology
• Liquid Biopsy
• +۳ مورد دیگر

Klaus Pantel is a Professor at the Institute of Tumor Biology within the University Medical Center Hamburg-Eppendorf , a leading institution in biomedical research. His work focuses on liquid biopsy technologies, particularly the detection and characterization of circulating tumor cells (CTCs) and cell-free DNA for cancer diagnosis, treatment monitoring, and resistance mechanisms. Key research projects include European Liquid Biopsy Society (ELBS) initiatives, RAI2 protein function in castration-resistant prostate cancer, and brain metastasis prevention strategies . His recent publications highlight advances in machine learning-based CTC detection , immune checkpoint inhibition biomarkers , and metastasis biology . He contributes to clinical translation through PREDICT Global Pooled Analysis and collaborations with EFPIA partners for postdoctoral funding.

• Peptide Chemistry
• Bioorganic Chemistry
• Enzyme Inhibition
• +۳ مورد دیگر

Dr. Agata Gitlin-Domagalska serves as an Adjunct Professor at the Faculty of Chemistry, University of Gdańsk, where she leads research in the Department of Molecular Biochemistry and Laboratory of Bioorganic Chemistry. Her work bridges peptide chemistry and bioorganic drug design, focusing on innovative synthetic strategies and therapeutic applications. Academic Affiliation: Faculty of Chemistry, University of Gdańsk Department: Department of Molecular Biochemistry Laboratory: Laboratory of Bioorganic Chemistry Specializing in peptide synthesis and prodrug development , Dr. Gitlin-Domagalska investigates strategies to enhance oral bioavailability of charged peptides through lipophilic charge masking and non-covalent inhibition of serine proteases like matriptase and furin . Her research extends to antimicrobial peptide conjugates with dual therapeutic functions and Zika virus suppression via protease inhibition. Recent publications highlight her expertise in peptide splicing mechanisms , solid-phase synthesis optimization , and nanoparticle-based delivery . She has developed cyclic RGD prodrugs for targeted intestinal permeability and bicyclic furin inhibitors using combinatorial chemistry approaches. Her work contributes to antibiotic conjugates with leukemia-selective antifungal activity , neuroprotective humanin analogs , and vasopressin derivatives with expanded therapeutic potential. Current trends emphasize matriptase-selective inhibitors and earthworm-derived antimicrobial nanoparticles . Dr. Gitlin-Domagalska employs model membrane biosensing for drug-membrane interaction studies and has pioneered high-shear mixing techniques to improve amide bond formation efficiency in peptide synthesis processes.

• Virology
• Medical Microbiology
• Infectious Diseases
• +۳ مورد دیگر

Nicola Clementi serves as an Associate Professor of Medical Microbiology and Virology at Vita-Salute San Raffaele University in Milan, Italy, with active clinical and research affiliation at San Raffaele Scientific Institute (IRCCS). His academic credentials include Board Certification in Medical Microbiology and Virology (2010) from Vita-Salute San Raffaele University and a Master's degree in Biological Sciences (2006) from Università Politecnica delle Marche, Ancona. His educational background features: Master of Biological Sciences, Università Politecnica delle Marche, Ancona, Italy (2006) Board Certification in Medical Microbiology and Virology, Vita-Salute San Raffaele University, Milan, Italy (2010) Clementi's research centers on clinical virology and medical microbiology with emphasis on bacterial and viral pathogen dynamics. His work spans sexually transmitted infections (LGV, gonorrhea), emerging viral outbreaks (mpox, SARS-CoV-2), neonatal viral hepatitis , and microbiome-immune interactions in immunotherapy. He employs epidemiological surveillance, mutational profiling, and clinical cohort analysis to address antimicrobial resistance trends and therapeutic efficacy challenges within Italian healthcare settings. His 2024 publications reveal a focus on urgent public health threats through high-impact clinical studies. Key trends include optimizing antibiotic regimens for STIs, investigating immunological mechanisms in viral hepatitis, analyzing SARS-CoV-2 mutational responses to ribavirin therapy, and exploring microbiome modulation to reduce immunotherapy toxicity. The work heavily leverages Italian patient cohorts (Lombardy region) and demonstrates interdisciplinary approaches bridging virology, bacteriology, and immunology. No scientific awards are documented in the provided source material. While formal student lists and grant details are absent from the scraped data, his editorial roles and publication volume suggest active academic mentoring. Clementi serves as Review Editor for Virology at Frontiers in Microbiology and Guest Associate Editor for Experimental Pharmacology at Frontiers in Pharmacology, indicating leadership in scholarly peer review despite no explicit grant mentions. He operates within San Raffaele Scientific Institute (IRCCS) research ecosystem, evidenced by co-authorship with clinicians and microbiologists from this tertiary hospital. His network includes collaborators like Gabriel Siracusano (IRCCS) and Mauro Pistello (University of Pisa), with 46 active professional connections reflecting engagement in Italy's infectious disease community.

Tijana Đuričićمشاهده پروفایل

مدرس ارشد

• Environmental Engineering
• Chemical Engineering
• Water Treatment
• +۳ مورد دیگر

Tijana Đuričić is a Senior Lecturer at the Faculty of Technology, University of Banja Luka, specializing in chemical engineering and environmental technologies. Her work focuses on electrochemical processes for wastewater treatment, corrosion inhibition, and sustainable materials. She contributes to academic programs at both bachelor’s and master’s levels, teaching courses related to chemical engineering and environmental science. Her research interests revolve around advanced oxidation processes, electrocoagulation, and the application of green chemistry principles in industrial contexts. Notable projects include treating cyanide-free zinc plating wastewater, optimizing phenol degradation via electrooxidation, and developing corrosion-resistant materials using novel inhibitors. She has collaborated on interdisciplinary initiatives addressing landfill leachate treatment and solar-driven water purification systems. Đuričić has authored or co-authored over 30 peer-reviewed articles in journals like Journal of the Electrochemical Society and Hemijska Industrija , with a focus on environmental engineering and electrochemistry. She actively participates in international conferences, presenting breakthroughs in electrochemical sensor development and eco-friendly wastewater solutions. Her work often intersects with industry partners, emphasizing practical applications of research in real-world scenarios. Current projects include Napredne (zelene) tehnologije za tretman otpadnih voda (Advanced Green Technologies for Wastewater Treatment) and Elektrohemijski tretman otpadnih voda primjenom energije iz obnovljivih izvora (Electrochemical Treatment of Wastewater Using Renewable Energy), funded by national and international grants. These initiatives aim to reduce environmental impact through innovative, sustainable methods. Her professional network spans academic and industrial collaborators across the Balkans, fostering knowledge exchange on emerging pollutants and eco-technologies. Đuričić’s contributions highlight her dedication to advancing both theoretical and applied aspects of environmental and chemical engineering.

Eric Y. Chengمشاهده پروفایل

استاد

• Drug Discovery
• Natural Products
• Anti-Cancer Agents
• +۴ مورد دیگر

Eric Y. Cheng is a Professor in the Department of Pharmaceutical Sciences at the UNT System College of Pharmacy, University of North Texas Health Science Center. His research focuses on discovering bioactive natural products from microorganisms for cancer, infectious disease, and anti-aging therapies. He leads projects on histone deacetylase inhibitors (HDACi) like Thailandepsin A and FK228, and collaborates on oncolytic virus engineering for chemoimmunotherapy. Education: BS in Microbiology (Huazhong Agricultural University), MS in Phytochemistry (Chinese Academy of Sciences Institute of Botany), PhD in Botany & Microbiology (Michigan State University). Research emphasizes drug discovery via microbial natural products and synthetic biology approaches. Key areas include metabolic engineering of Burkholderia thailandensis for thailanstatin production, development of HDAC inhibitors, and exploring anti-glaucoma agents. Over 66 publications and 7 sponsored projects since 1998, with notable work on leinamycin biosynthesis and fermentation optimization. Grants include NCI-funded projects on histone deacetylase inhibitors and UTSW grants for prostate cancer research. Collaborative projects span institutions globally, focusing on drug development pipelines and translational applications.

Rutilio A. Frattiمشاهده پروفایل

استاد

• Membrane Biology
• Ion Channels
• Protein Dynamics
• +۵ مورد دیگر

Rutilio A. Fratti is a Professor of Biochemistry and Biophysics & Quantitative Biology at the University of Illinois, affiliated with the College of Liberal Arts & Sciences and the School of Molecular & Cellular Biology. His research focuses on protein-lipid interactions, membrane fusion, and lipid metabolism, particularly in the context of diseases like cancer, diabetes, and Alzheimer's. He earned his B.S. from California State University, Long Beach (1992), Ph.D. from the University of Michigan (2002), and completed postdoctoral work at Dartmouth Medical School (2002-2006). Key research interests include regulatory lipids (e.g., phosphatidic acid, phosphoinositides) and their roles in membrane microdomains, SNARE protein function, and drug discovery targeting fungal pathogens. His lab uses yeast vacuoles and synthetic vesicles to study lipid-protein interactions during membrane fusion. Publications highlight advancements in methods like Bio-Layer Interferometry, microscale thermophoresis, and spectroscopic techniques for studying lipid-protein interactions. Collaborations span drug discovery (e.g., SQ109 antifungal mechanisms) and mechanistic insights into Sec18 protein dynamics and Ypt7 regulation. Affiliated with the Center for Biophysics & Quantitative Biology, his work bridges fundamental lipid biology with translational applications in metabolic and infectious diseases.

Nathaniel R. Landauمشاهده پروفایل

استاد

• Virology
• Immunology
• Innate Immunity
• +۴ مورد دیگر

Nathaniel R. Landau is a Professor in the Department of Microbiology at NYU Grossman School of Medicine. His research spans HIV molecular biology, dendritic cell immunology, lentiviral vector vaccine development, and SARS-CoV-2 therapeutics. He has pioneered tools for neutralizing antibody assays and developed a soluble ACE2-based therapeutic for coronavirus infections. PhD in Biology from Massachusetts Institute of Technology Postdoctoral Fellowships: University of California, San Francisco (Microbiology & Immunology); MIT Biology Department Dr. Landau's work focuses on innate immunity mechanisms, including restriction factors like APOBEC3 and SAMHD1 that inhibit retroviruses, and how viruses counteract these defenses. His lab has engineered lentiviral vectors that overcome SAMHD1 barriers for dendritic cell transduction and developed second-generation dendritic cell vaccines for HIV and cancer. Recent research includes creating SARS-CoV-2 spike-pseudotyped lentiviruses for neutralization assays and a recombinant ACE2 microbody with enhanced antiviral activity. The lab has validated these tools in convalescent sera studies and developed rapid assays for antibody titers. Key trends in his publications include innate immune evasion, lentiviral vector innovations, and cross-disciplinary approaches to viral pathogenesis. His team has automated neutralization assays using robotic platforms to process large sample volumes efficiently. Dr. Landau's laboratory has contributed to understanding how toll-like receptor agonists like imiquimod induce antiviral states via ISGs, and explored Vpr/Vpx accessory protein functions in lentivirus immune escape. Current projects extend these findings toward immunotherapeutic cancer strategies.

Timothy C. Meredithمشاهده پروفایل

دانشیار

• Bacterial Cell Envelope Biosynthesis
• Lipoprotein Biosynthesis
• Functional Genomics
• +۹ مورد دیگر

Timothy C. Meredith is an Associate Professor in the Department of Biochemistry and Molecular Biology at Pennsylvania State University. His career spans academic research and industry roles at Merck Research Laboratories and Novartis Institutes for Research, with a postdoctoral fellowship at Harvard Medical School and a return to Harvard as an instructor.

• Clinical Trials
• Epidemiology
• Kidney Disease
• +۵ مورد دیگر

Scientia Professor Vlado Perkovic serves as the Provost at UNSW Sydney, having previously held the position of Dean of the Faculty of Medicine and Health at the same institution. He is also a Professorial Fellow at The George Institute for Global Health and was formerly a Staff Specialist in Nephrology at the Royal North Shore Hospital. Professor Perkovic completed his undergraduate medical training at The Royal Melbourne Hospital and earned his Doctor of Philosophy from the University of Melbourne. Professor Perkovic is a leading researcher in clinical trials and epidemiology, with a specialized focus on preventing the progression of kidney disease and its complications. His work has significantly influenced clinical practice through major international clinical trials and contributions to Australian and global guidelines in kidney disease, cardiovascular risk assessment, and blood pressure management. His research spans clinical trial methodology, epidemiology of kidney disease, diabetes complications, and implementation of evidence-based medicine. Analysis of his recent publications reveals a strong emphasis on combination therapies for kidney protection, population-level impacts of novel medications like SGLT2 inhibitors, and long-term benefits of cardiovascular and renal protective agents. His work frequently involves large-scale clinical trial data analysis, particularly from the CANVAS Program and CREDENCE trial, which have shaped treatment approaches for patients with diabetes and chronic kidney disease worldwide. Fellow of the Royal Australasian College of Physicians Fellow of the Australian Academy of Health and Medical Sciences Fellow of the American Society of Nephrology Professor Perkovic has secured substantial research funding and has mentored numerous students and early-career researchers in nephrology. His leadership extends beyond research to academic administration and healthcare policy development. As Provost, he plays a key role in shaping the academic direction of UNSW while maintaining active involvement in clinical research that continues to influence global kidney disease management.

Shana Stoddardمشاهده پروفایل

دانشیار

• Autoimmune disorders
• Protein engineering
• Computational chemistry
• +۶ مورد دیگر

Dr. Shana Stoddard is an Associate Professor of Chemistry at Rhodes College, where she leads the Molecular Immunotherapeutics Research (MIR) lab. Her research program focuses on improving patient outcomes with autoimmune disorders, cancer, neurological disorders, and coronaviruses through protein engineering, computational chemistry, and rational drug design. Dr. Stoddard received her educational training from: Postdoctoral Researcher at St. Jude Children's Research Hospital (Diagnostic Imaging) Ph.D. in Chemistry and Biochemistry from University of Mississippi M.Ed. in Curriculum and Instruction (emphasis Special Education) from Freed-Hardeman University B.S. in Chemistry from Prairie View A&M University Dr. Stoddard's research interests span multiple areas of biomedical science with a focus on therapeutic development. Her work in autoimmune disorders centers on primary membranous nephritis (PMN), where she develops auto-antibody-specific inhibitors and antigen-specific therapies. In cancer research , she focuses on designing selective histone deacetylase (HDAC) inhibitors for various cancer types, particularly targeting HDAC8 for neuroblastoma treatment. Her lab also works on neurological disorders , developing HDAC4 inhibitors for Huntington's disease and glioblastoma. During the COVID-19 pandemic, her lab pivoted to coronavirus antiviral development , creating peptide-based fusion inhibitors and protease inhibitors. Additionally, Dr. Stoddard is deeply committed to diversity and equity in STEM education , developing pedagogical approaches to create more inclusive classrooms. Analysis of Dr. Stoddard's recent publications reveals a consistent focus on structure-based drug design across multiple therapeutic areas. Her work employs computational chemistry approaches to model protein structures and design inhibitors with improved selectivity. A significant portion of her research targets histone deacetylases (HDACs), with emphasis on achieving isozyme selectivity among the 18 different HDAC enzymes. Her lab has made contributions to understanding protein structures involved in autoimmune kidney diseases and developed computational models of previously uncharacterized proteins. Dr. Stoddard has received numerous prestigious awards recognizing both her research and mentorship: 2025 – LMI Mellon Fellow 2024 – Lloyd N Ferguson Young Scientist Award from NOBCChE 2024 – Sigma Xi, The Scientific Research Honor Society inductee 2024 – Ruth Kirschstein Diversity in Science Award from ASBMB 2023 – Tyrone Mitchell Mentor-on-the-Map Award from NOBCChE 2023 – Silvia Ronco Innovative Mentor Award from CUR Chemistry 2022 – Henry C. McBay Outstanding Teaching Award from NOBCChE 2021 – Outstanding Mentor of the year Award CUR Health Sciences (Early Career Stage) 2021 – Accessibility and Inclusivity Advocate of the Year: Campus Life Award (Rhodes College) Dr. Stoddard is renowned for her exceptional mentorship of undergraduate researchers, particularly from underrepresented groups in STEM. She established the STEM Cohort Mentoring program at Rhodes in 2017 to support diverse students pursuing STEM careers. Her lab has produced numerous undergraduate co-authors on peer-reviewed publications across multiple disciplines. She has successfully guided many students into medical schools and graduate programs. Dr. Stoddard has secured competitive funding for her research, including participation in the Project Kaleidoscope STEM Leadership Institute held by the American Association of Colleges & Universities. The Molecular Immunotherapeutics Research (MIR) lab at Rhodes College is a vibrant research environment where undergraduate students work alongside Dr. Stoddard on cutting-edge biomedical research. The lab currently pursues four major research projects: 1) Protein Engineering and Development of Antigen Specific Therapeutics for Autoimmune Disorders; 2) Modeling and Investigation of Structure and Function Relationships of Unsolved Protein Structures; 3) Design, Synthesis, and Biological Testing of Novel Therapeutic Compounds for Cancer, Autoimmune, and Neurological Disorders; and 4) Development of Broad-Spectrum Coronavirus Antivirals. The MIR lab collaborates with researchers at institutions including Boston University Medical College, University of Mississippi, and St. Jude Children's Research Hospital.

Danielle Dubeمشاهده پروفایل

استاد

• Chemical Biology
• Glycobiology
• Antibiotic Resistance
• +۳ مورد دیگر

Danielle Dube is the Norma L. and Roland G. Ware, Jr. Professor of Chemistry and Biochemistry and Chair of the Chemistry Department at Bowdoin College. A chemical biologist by training, she received her PhD from UC Berkeley and completed postdoctoral work at Stanford University. Her research focuses on bacterial surface glycans linked to pathogenesis, particularly in Helicobacter pylori , where she develops chemical tools to study and disrupt glycan-mediated interactions. Education : Cornell University (AB in Biology), UC Berkeley (PhD in Chemistry), Stanford University (Postdoctoral) Teaching : Biochemistry, Chemical Biology, General Chemistry, Drug Discovery courses Research Highlights : Structural characterization of H. pylori glycans Development of metabolic inhibitors for glycan biosynthesis Creation of imaging probes for bacterial glycocalyx Immune recognition enhancement through glycan modification Antibiotic hypersensitization via glycan disruption Scientific Recognition : 2022: Recognized in Nobel Prize awarded research by Prof. Carolyn Bertozzi 2018: Recipient of external grant for women scientists 2014: Collaborator on $18.4M INBRE grant Lab & Collaborations : Leads the Dube Research Laboratory at Bowdoin, specializing in chemical approaches to bacterial glycobiology. Collaborates with biochemistry and microbiology teams on antibiotic resistance solutions.

Lisa M. Coussensمشاهده پروفایل

استاد

• Tumor Immunology
• Cancer Microenvironment
• Inflammation in Cancer
• +۳ مورد دیگر

Lisa M. Coussens, PhD, is Chairwoman of the Department of Cell, Developmental & Cancer Biology and Interim Director of the Knight Cancer Institute at Oregon Health & Science University (OHSU), where she holds the Hildegard Lamfrom Endowed Chair in Basic Science. Her research program investigates immune cell functions in solid tumor development, with emphasis on how leukocytes influence cancer progression and therapeutic responses. Using preclinical models of mesothelioma, breast, pancreatic, and head/neck cancers, her lab identifies immunotherapy targets that have advanced to clinical trials for metastatic cancers. Education B.A., San Francisco State University, 1980 Ph.D., University of California, 1993 Postdoctoral Fellowship, University of California San Francisco (Douglas Hanahan Lab) Research Focus Dr. Coussens leads a translational research program examining how immune cells regulate tumor development and therapy responses. Her work integrates molecular oncology, immunology, and preclinical modeling to identify: 1) Immune pathways co-opted by developing tumors, 2) Mechanisms of leukocyte-mediated therapy resistance, and 3) Biomarkers for immunotherapy response. Current work emphasizes spatial analysis of tumor-immune interactions using multiplexed imaging and computational approaches. Her recent publications reflect strong emphasis on tumor microenvironment dynamics, immunotherapy mechanisms, and translational applications in pancreatic, breast, and head/neck cancers. Studies frequently incorporate spatial biology techniques, clinical correlation analyses, and novel therapeutic combinations targeting immune pathways. Honors & Awards National Academy of Sciences Member (2023) National Academy of Medicine Member (2024) AACR President (2022-2023) Susan G. Komen Brinker Award (2018) Fellow of AACR Academy (2019) Fellow of AAAS (2018) Rosalind E. Franklin Award, NCI (2015) Honorary Doctorate, University of Buenos Aires (2018) Princess Takamatsu Memorial Lectureship (2018) European Academy of Tumor Immunology Career Award (2018) Gertrude B. Elion Award (2001) Charlotte Friend Lectureship (2012) Margaret L. Kripke Legend Award (2023) Johns Hopkins Heroine of Public Health (2024) Fellow of Academy of ImmunoOncology (2022) Dr. Coussens directs translational research programs at OHSU's Knight Cancer Institute and leads multidisciplinary collaborations investigating tumor-immune crosstalk. Her laboratory develops innovative preclinical platforms for evaluating combination immunotherapies.